Ed Schoonveld has 30+ years of experience in pharmaceutical pricing and access. He is currently Managing Partner of the Value and Access Practice with ZS Associates. He led global pricing functions for Wyeth, Lilly and BMS and consulting practices in Cambridge Pharma/IMS and Analytica International.

List of Figures, List of Tables, List of Abbreviations, Foreword by Andrea Mantovani, Acknowledgements, Preface, About the Author, Introduction, Part A The Challenges of Drug Pricing and Market Access, 1 Why is drug pricing different? 2 The Age of Value and Affordability, 3 The Access Journey, 4 Fair Pricing, Part B Traveling the Access Journey, 5 Payers, 6 Medical Community, 7 Provider Organizations, 8 Patients, Part C Pricing and Payer Management Techniques, 9 Fundamentals of Pricing, 10 Reference-Based Pricing, 11 Health Economics and Outcomes Research, 12 Attributes, Benefits, Value and Price, Part D Structured Access and Pricing Approaches, 13 Pricing and Drug Development, 14 Payer Segmentation, 15 The PODiUM Framework, 16 BEST Framework, 17 Development Options and Decisions, 18 Value Story and Messaging, Part E Developing an Integrated Global Strategy, 19 Developing a Global Pricing Strategy, 20 Public Policy, 21 Oncology and Orphan Drugs, 22 Gene Therapy Pricing and Funding, 23 Biosimilars, 24 Payer and Pricing Research, Part F Access and Pricing Strategy Implementation, 25 Organizing for Access, 26 Access and Price Negotiations, 27 Value-based Agreements, 28 Creating Win-Win Deals, Part G Key Health Care Systems, 29 United States, 30 Canada, 31 France, 32 Germany, 33 Italy, 34 Spain, 35 United Kingdom, 36 Japan, 37 Australia, 38 Brazil, 39 China, 40 India, 41 South Korea, References, Index